Channelpedia

Nav1.7 Channel

382 automatically matched literature references

2

Gupta B et al. Antinociceptive properties of shikonin: in vitro and in vivo studies.
Can. J. Physiol. Pharmacol., 2016 Mar 6 , (1-9).

5

Chambers C et al. High-Throughput Screening of NaV1.7 Modulators Using a Giga-Seal Automated Patch Clamp Instrument.
Assay Drug Dev Technol, 2016 Mar , 14 (93-108).

12

Frost JM et al. Substituted Indazoles as Nav1.7 Blockers for the Treatment of Pain.
J. Med. Chem., 2016 Apr 14 , 59 (3373-91).

23

26

Stadler T et al. Erythromelalgia mutation Q875E Stabilizes the activated state of sodium channel Nav1.7.
J. Biol. Chem., 2015 Mar 6 , 290 (6316-25).

28

30

Hoeijmakers JG et al. Painful peripheral neuropathy and sodium channel mutations.
Neurosci. Lett., 2015 Jun 2 , 596 (51-9).

32

Bogdanova-Mihaylova P et al. SCN9A-associated congenital insensitivity to pain and anosmia in an Irish patient.
J. Peripher. Nerv. Syst., 2015 Jun , 20 (86-7).

39

Lynch SM et al. Dibenzazepines and dibenzoxazepines as sodium channel blockers.
Bioorg. Med. Chem. Lett., 2015 Jan 1 , 25 (43-7).

40

Lynch SM et al. N-Aryl azacycles as novel sodium channel blockers.
Bioorg. Med. Chem. Lett., 2015 Jan 1 , 25 (48-52).

51

Szabat M et al. High-content screening identifies a role for Na(+) channels in insulin production.
R Soc Open Sci, 2015 Dec , 2 (150306).

55

Habib AM et al. Sodium channels and pain.
Handb Exp Pharmacol, 2015 , 227 (39-56).

60

Doran C et al. Mouse DRG Cell Line with Properties of Nociceptors.
PLoS ONE, 2015 , 10 (e0128670).

63

King GF et al. No gain, no pain: NaV1.7 as an analgesic target.
ACS Chem Neurosci, 2014 Sep 17 , 5 (749-51).

67

Ho GD et al. Discovery of pyrrolo-benzo-1,4-diazines as potent Na(v)1.7 sodium channel blockers.
Bioorg. Med. Chem. Lett., 2014 Sep 1 , 24 (4110-3).

68

Greaves E et al. Elevated peritoneal expression and estrogen regulation of nociceptive ion channels in endometriosis.
J. Clin. Endocrinol. Metab., 2014 Sep , 99 (E1738-43).

71

73

Snyder LM et al. An SCN9A variant, known to cause pain, is now found to cause itch.
Pain, 2014 Sep , 155 (1677-8).

74

Devigili G et al. Paroxysmal itch caused by gain-of-function Nav1.7 mutation.
Pain, 2014 Sep , 155 (1702-7).

75

Ramirez JD et al. Null mutation in SCN9A in which noxious stimuli can be detected in the absence of pain.
Neurology, 2014 Oct 21 , 83 (1577-80).

78

Hoeijmakers JG et al. Channelopathies, painful neuropathy, and diabetes: which way does the causal arrow point?
Trends Mol Med, 2014 Oct , 20 (544-50).

81

Zhang Q et al. Na+ current properties in islet α- and β-cells reflect cell-specific Scn3a and Scn9a expression.
J. Physiol. (Lond.), 2014 Nov 1 , 592 (4677-96).

85

89

Thériault O et al. Modulation of peripheral Na(+) channels and neuronal firing by n-butyl-p-aminobenzoate.
Eur. J. Pharmacol., 2014 Mar 15 , 727 (158-66).

91

Black JA et al. Nav1.9 expression in magnocellular neurosecretory cells of supraoptic nucleus.
Exp. Neurol., 2014 Mar , 253 (174-9).

93

Coleman N et al. New Positive KCa Channel Gating Modulators with Selectivity for KCa3.1.
Mol. Pharmacol., 2014 Jun 23 , ().

94

Bennett DL et al. Painful and painless channelopathies.
Lancet Neurol, 2014 Jun , 13 (587-99).

96

97

Foadi N et al. Inhibition of voltage-gated Na⁺ channels by the synthetic cannabinoid ajulemic acid.
Anesth. Analg., 2014 Jun , 118 (1238-45).

98

Brouwer BA et al. Painful neuropathies: the emerging role of sodium channelopathies.
J. Peripher. Nerv. Syst., 2014 Jun , 19 (53-65).

99

Minett MS et al. Pain without nociceptors? Nav1.7-independent pain mechanisms.
Cell Rep, 2014 Jan 30 , 6 (301-12).

102

Shorer Z et al. A novel mutation in SCN9A in a child with congenital insensitivity to pain.
Pediatr. Neurol., 2014 Jan , 50 (73-6).

109

Yip TS et al. SCN1A variations and response to multiple antiepileptic drugs.
Pharmacogenomics J., 2014 Aug , 14 (385-9).

110

Themistocleous AC et al. The clinical approach to small fibre neuropathy and painful channelopathy.
Pract Neurol, 2014 Apr 28 , ().

112

Vasylyev DV et al. Dynamic-clamp analysis of wild-type human Nav1.7 and erythromelalgia mutant channel L858H.
J. Neurophysiol., 2014 Apr , 111 (1429-43).

114

Laedermann CJ et al. Ubiquitylation of voltage-gated sodium channels.
Handb Exp Pharmacol, 2014 , 221 (231-50).

116

Zimmer T et al. Voltage-gated sodium channels in the mammalian heart.
Glob Cardiol Sci Pract, 2014 , 2014 (449-63).

121

Minett MS et al. Significant determinants of mouse pain behaviour.
PLoS ONE, 2014 , 9 (e104458).

123

127

129

Zhang XY et al. Gain-of-function mutations in SCN11A cause familial episodic pain.
Am. J. Hum. Genet., 2013 Nov 7 , 93 (957-66).

132

Estacion M et al. A new Nav1.7 mutation in an erythromelalgia patient.
Biochem. Biophys. Res. Commun., 2013 Mar 1 , 432 (99-104).

137

McCormack K et al. Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels.
Proc. Natl. Acad. Sci. U.S.A., 2013 Jul 16 , 110 (E2724-32).

139

Tsunozaki M et al. A 'toothache tree' alkylamide inhibits Aδ mechanonociceptors to alleviate mechanical pain.
J. Physiol. (Lond.), 2013 Jul 1 , 591 (3325-40).

141

Waxman SG Painful Na-channelopathies: an expanding universe.
Trends Mol Med, 2013 Jul , 19 (406-9).

148

Zhang LM et al. [Association between mutations of SCN9A gene and pain related to Parkinsonism].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2013 Feb , 30 (17-20).

149

Tanzi S et al. Ion channel recordings on an injection-molded polymer chip.
Lab Chip, 2013 Dec 21 , 13 (4784-93).

150

Staunton CA et al. Ion channels and osteoarthritic pain: potential for novel analgesics.
Curr Pain Headache Rep, 2013 Dec , 17 (378).

151

Doppler K et al. [Neuropathic pain associated with Nav1.7 mutations: clinical picture and treatment].
Nervenarzt, 2013 Dec , 84 (1428-35).

154

Dustrude ET et al. CRMP2 protein SUMOylation modulates NaV1.7 channel trafficking.
J. Biol. Chem., 2013 Aug 23 , 288 (24316-31).

157

Yuan J et al. Hereditary sensory and autonomic neuropathy type IID caused by an SCN9A mutation.
Neurology, 2013 Apr 30 , 80 (1641-9).

159

Klein CJ et al. Infrequent SCN9A mutations in congenital insensitivity to pain and erythromelalgia.
J. Neurol. Neurosurg. Psychiatr., 2013 Apr , 84 (386-91).

160

Kim MK et al. Autonomic dysfunction in SCN9A-associated primary erythromelalgia.
Clin. Auton. Res., 2013 Apr , 23 (105-7).

162

168

Zufall F et al. Link between pain and olfaction in an inherited sodium channelopathy.
Arch. Neurol., 2012 Sep 1 , 69 (1119-23).

171

Goldberg YP et al. Human Mendelian pain disorders: a key to discovery and validation of novel analgesics.
Clin. Genet., 2012 Oct , 82 (367-73).

172

Hoeijmakers JG et al. Genetic aspects of sodium channelopathy in small fiber neuropathy.
Clin. Genet., 2012 Oct , 82 (351-8).

173

Greenbaum L et al. Contribution of genetic variants to pain susceptibility in Parkinson disease.
Eur J Pain, 2012 Oct , 16 (1243-50).

174

Klement G et al. Identification of Novel NaV1.7 Antagonists Using High Throughput Screening Platforms.
Comb. Chem. High Throughput Screen., 2012 Nov 1 , 15 (713-20).

177

Raouf R et al. Sodium channels and mammalian sensory mechanotransduction.
, 2012 Mar 26 , 8 (21).

178

180

Liu P et al. Modulation of neuronal sodium channels by the sea anemone peptide BDS-I.
J. Neurophysiol., 2012 Jun , 107 (3155-67).

182

Nguyen HN et al. Discovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonists.
Bioorg. Med. Chem. Lett., 2012 Jan 15 , 22 (1055-60).

184

Faber CG et al. Gain of function Naν1.7 mutations in idiopathic small fiber neuropathy.
Ann. Neurol., 2012 Jan , 71 (26-39).

194

Weinkauf B et al. Local Gene Expression Changes after UV-Irradiation of Human Skin.
PLoS ONE, 2012 , 7 (e39411).

196

205

Freilich ER et al. Novel SCN1A mutation in a proband with malignant migrating partial seizures of infancy.
Arch. Neurol., 2011 May , 68 (665-71).

206

Shou WT et al. [Role of voltage-sodium channels in neuropathic pain].
Zhejiang Da Xue Xue Bao Yi Xue Ban, 2011 Mar , 40 (217-21).

209

Chowdhury S et al. Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain.
Bioorg. Med. Chem. Lett., 2011 Jun 15 , 21 (3676-81).

214

215

Widmark J et al. Differential evolution of voltage-gated sodium channels in tetrapods and teleost fishes.
Mol. Biol. Evol., 2011 Jan , 28 (859-71).

216

Choi JS et al. Paroxysmal extreme pain disorder: a molecular lesion of peripheral neurons.
Nat Rev Neurol, 2011 Jan , 7 (51-5).

218

Ho C et al. Single-cell analysis of sodium channel expression in dorsal root ganglion neurons.
Mol. Cell. Neurosci., 2011 Jan , 46 (159-66).

225

Weiss J et al. Loss-of-function mutations in sodium channel Nav1.7 cause anosmia.
Nature, 2011 Apr 14 , 472 (186-90).

226

Gurkiewicz M et al. Kinetic modeling of Nav1.7 provides insight into erythromelalgia-associated F1449V mutation.
J. Neurophysiol., 2011 Apr , 105 (1546-57).

230

Tyagarajan S et al. Substituted biaryl pyrazoles as sodium channel blockers.
Bioorg. Med. Chem. Lett., 2010 Sep 15 , 20 (5480-3).

232

233

234

Lötsch J et al. Pharmacogenetics of new analgesics.
, 2010 Oct 13 , ().

235

Ahn HS et al. A new Nav1.7 sodium channel mutation I234T in a child with severe pain.
Eur J Pain, 2010 Oct , 14 (944-50).

238

239

Reimann F et al. Pain perception is altered by a nucleotide polymorphism in SCN9A.
Proc. Natl. Acad. Sci. U.S.A., 2010 Mar 16 , 107 (5148-53).

240

Meisler MH et al. Sodium channel gene family: epilepsy mutations, gene interactions and modifier effects.
J. Physiol. (Lond.), 2010 Jun 1 , 588 (1841-8).

242

Lampert A et al. Sodium channelopathies and pain.
Pflugers Arch., 2010 Jul , 460 (249-63).

243

Clare JJ Targeting voltage-gated sodium channels for pain therapy.
Expert Opin Investig Drugs, 2010 Jan , 19 (45-62).

245

Fischer TZ et al. Familial pain syndromes from mutations of the NaV1.7 sodium channel.
Ann. N. Y. Acad. Sci., 2010 Jan , 1184 (196-207).

246

Cregg R et al. Pain Channelopathies.
, 2010 Feb 8 , ().

255

Krupp JJ et al. Linkage analysis and functional evaluation of inherited clinical pain conditions.
Methods Mol. Biol., 2010 , 617 (309-25).

258

Kurban M et al. A nonsense mutation in the SCN9A gene in congenital insensitivity to pain.
Dermatology (Basel), 2010 , 221 (179-83).

260

Priest BT Future potential and status of selective sodium channel blockers for the treatment of pain.
Curr Opin Drug Discov Devel, 2009 Sep , 12 (682-92).

263

Zsiros E et al. Developmental switch of the expression of ion channels in human dendritic cells.
J. Immunol., 2009 Oct 1 , 183 (4483-92).

264

Dib-Hajj SD et al. Voltage-gated sodium channels: therapeutic targets for pain.
Pain Med, 2009 Oct , 10 (1260-9).

265

Schmalhofer WA et al. A KV2.1 gating modifier binding assay suitable for high throughput screening.
Channels (Austin), 2009 Nov , 3 (437-47).

266

Nilsen KB et al. Two novel SCN9A mutations causing insensitivity to pain.
Pain, 2009 May , 143 (155-8).

267

268

Fischer TZ et al. A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia.
Ann. Neurol., 2009 Jun , 65 (733-41).

270

Martinez-Lavin M et al. Dorsal root ganglia, sodium channels, and fibromyalgia sympathetic pain.
Med. Hypotheses, 2009 Jan , 72 (64-6).

271

Meguro K et al. Function and role of voltage-gated sodium channel NaV1.7 expressed in aortic smooth muscle cells.
Am. J. Physiol. Heart Circ. Physiol., 2009 Jan , 296 (H211-9).

272

Danziger N et al. [Congenital insensitivity to pain]
Rev. Neurol. (Paris), 2009 Feb , 165 (129-36).

277

Estacion M et al. A sodium channel gene SCN9A polymorphism that increases nociceptor excitability.
Ann. Neurol., 2009 Dec , 66 (862-6).

279

Black JA et al. Sodium channel activity modulates multiple functions in microglia.
Glia, 2009 Aug 1 , 57 (1072-81).

280

Macefield VG Developments in autonomic research: a review of the latest literature.
Clin. Auton. Res., 2009 Aug , 19 (193-6).

284

Skali Dahbi S et al. [Primary erythermalgia: efficacy of oxcarbazepine]
, 2009 Apr , 136 (337-40).

285

Gao N et al. Voltage-gated sodium channels in taste bud cells.
, 2009 , 10 (20).

291

Wang CF et al. Use of bulleyaconitine A as an adjuvant for prolonged cutaneous analgesia in the rat.
Anesth. Analg., 2008 Oct , 107 (1397-405).

292

294

London C et al. Imidazopyridines: a novel class of hNav1.7 channel blockers.
Bioorg. Med. Chem. Lett., 2008 Mar 1 , 18 (1696-701).

297

Wang GK et al. Block of persistent late Na+ currents by antidepressant sertraline and paroxetine.
J. Membr. Biol., 2008 Mar , 222 (79-90).

301

Ebermann I et al. Double homozygosity for mutations of AGL and SCN9A mimicking neurohepatopathy syndrome.
Neurology, 2008 Jun 10 , 70 (2343-4).

303

Dray A Neuropathic pain: emerging treatments.
, 2008 Jul , 101 (48-58).

304

Young FB When adaptive processes go awry: gain-of-function in SCN9A.
Clin. Genet., 2008 Jan , 73 (34-6).

317

Dib-Hajj SD et al. Genetics and molecular pathophysiology of Na(v)1.7-related pain syndromes.
Adv. Genet., 2008 , 63 (85-110).

318

Kaneko Y et al. Expression of Nav1.1 in rat retinal AII amacrine cells.
Neurosci. Lett., 2007 Sep 7 , 424 (83-8).

319

Ahmad S et al. A stop codon mutation in SCN9A causes lack of pain sensation.
Hum. Mol. Genet., 2007 Sep 1 , 16 (2114-21).

322

Hoyt SB et al. Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain.
Bioorg. Med. Chem. Lett., 2007 Nov 15 , 17 (6172-7).

323

Montagna P Recent advances in the pharmacogenomics of pain and headache.
Neurol. Sci., 2007 May , 28 Suppl 2 (S208-12).

327

Takahashi K et al. A case of primary erythermalgia, wintry hypothermia and encephalopathy.
Neuropediatrics, 2007 Jun , 38 (157-9).

328

Huang X et al. [Expression and function of voltage-gated Na+ channel isoforms in rat sinoatrial node]
Nan Fang Yi Ke Da Xue Xue Bao, 2007 Jan , 27 (52-5).

329

Lee MJ et al. Characterization of a familial case with primary erythromelalgia from Taiwan.
J. Neurol., 2007 Feb , 254 (210-4).

330

Williams BS et al. Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7.
Biochemistry, 2007 Dec 18 , 46 (14693-703).

331

Drenth JP et al. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders.
J. Clin. Invest., 2007 Dec , 117 (3603-9).

332

Fertleman CR et al. Paroxysmal extreme pain disorder (previously familial rectal pain syndrome).
Neurology, 2007 Aug 7 , 69 (586-95).

333

Waxman SG Nav1.7, its mutations, and the syndromes that they cause.
Neurology, 2007 Aug 7 , 69 (505-7).

334

Zhang LL et al. Mutation hotspots of SCN9A in primary erythermalgia.
Br. J. Dermatol., 2007 Apr , 156 (767-9).

337

Dray A et al. Arthritis and pain. Future targets to control osteoarthritis pain.
Arthritis Res. Ther., 2007 , 9 (212).

340

Rogers M et al. The role of sodium channels in neuropathic pain.
Semin. Cell Dev. Biol., 2006 Oct , 17 (571-81).

341

Lampert A et al. Size matters: Erythromelalgia mutation S241T in Nav1.7 alters channel gating.
J. Biol. Chem., 2006 Nov 24 , 281 (36029-35).

342

Rush AM et al. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons.
Proc. Natl. Acad. Sci. U.S.A., 2006 May 23 , 103 (8245-50).

343

Han C et al. Sporadic onset of erythermalgia: a gain-of-function mutation in Nav1.7.
Ann. Neurol., 2006 Mar , 59 (553-8).

344

349

Catterall WA et al. Painful channels.
Neuron, 2006 Dec 7 , 52 (743-4).

350

Cox JJ et al. An SCN9A channelopathy causes congenital inability to experience pain.
Nature, 2006 Dec 14 , 444 (894-8).

351

Gardiner M Molecular genetics of infantile nervous system channelopathies.
Early Hum. Dev., 2006 Dec , 82 (775-9).

352

Diss JK et al. Brn-3a neuronal transcription factor functional expression in human prostate cancer.
Prostate Cancer Prostatic Dis., 2006 , 9 (83-91).

356

359

Marionneau C et al. Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart.
J. Physiol. (Lond.), 2005 Jan 1 , 562 (223-34).

362

Meisler MH et al. Sodium channel mutations in epilepsy and other neurological disorders.
J. Clin. Invest., 2005 Aug , 115 (2010-7).

364

Diss JK et al. A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo.
Prostate Cancer Prostatic Dis., 2005 , 8 (266-73).

368

Wood JN et al. Voltage-gated sodium channels and pain pathways.
J. Neurobiol., 2004 Oct , 61 (55-71).

374

McNulty MM et al. State-dependent mibefradil block of Na+ channels.
Mol. Pharmacol., 2004 Dec , 66 (1652-61).

375

Nassar MA et al. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain.
Proc. Natl. Acad. Sci. U.S.A., 2004 Aug 24 , 101 (12706-11).

376

379

Vijayaragavan K et al. Gating properties of Na(v)1.7 and Na(v)1.8 peripheral nerve sodium channels.
J. Neurosci., 2001 Oct 15 , 21 (7909-18).

381